2篇
您的检索式：作者名="Fengzhan Qin"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Phase Ⅲ Clinical Trials of the Cell Differentiation Agent-2 (CDA-2): Therapeutic Efficacy on Breast Cancer, Non-Small Cell Lung Cancer and Primary Hepatoma显示文摘 | Fengyi Feng Qing Lu Changquan Ling Yang Zhang Fengzhan Qin Huaqing Wang Wenxia Huang Shunchang Jiao Qiang Chen Mingzhong Li Yunzhong Zhu Meizhen Zhou Jun Ren Yetao Gao Jingpo Zhao Rongsheng Zheng Wenhua Zhao Zhiqiang Meng Fang Li Qizhong Zhang Dongli Zhao Liyan Xu Yongqiang Zhang Yanjun Zhang Zhenjiu Wang Shuonqi Liu Ming C. Liau | 2005 | Chinese Journal of Clinical Oncology2005，2，4： | 3 |
| 2 | A multicenter randomized phase Ⅱ trail of Oxaliplatin in the patients with colorectal cancer显示文摘Objective:To evaluate the efficacy and safety of Oxaliplatin in the patients with colorectal cancer. Methods:In a multicenter randomized control study,a total of 144 patients were divided into four groups:Oxaliplatin(Haitong)+5-FU,CF(group A) 41 cases;5-FU+CF(group B) 41 cases;Oxaliplatin(Haitong)+5-FU,CF(group C) 31 cases;Oxaliplatin(positive drug)+5-FU+CF(group D) 31 cases. Oxaliplatin combination regimen:L-OHP 130 mg/m2 i.v. infusion 2 h d1;CF 200 mg/m2 i.v. 2 h d1-d5;5-FU 300 mg/m2 i.v. infusion 4 h d1-d5(after CF). 5-FU+CF combination regimen:CF 200 mg/m2 i.v. infusion 2 h d1-d5,5-FU 300 mg/m2 i.v. infusion 4h d1-d5(after CF),the schedule was repeated every 3 weeks. The total cycles were 3. Results:After three circles treatment,overall response rate of 4 groups was 24.4%(group A),2.4%(group B),25.8%(group C) and 19.4%(group D),respectively. The response rate was significantly different between group A and group B(P < 0.01),but no significant difference was observed between group C and group D(P > 0.05). Conclusion:The Oxaliplatin(Haitong) for injection combination regimen is effective in the treatment of colorectal cancer. | Liqing Li Liangxi Pan Mingzhong Li Fengzhan Qin Lingyuan Zeng | 2008 | The Chinese-German Journal of Clinical Oncology2008，7，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员